Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Azitra Inc ( (AZTR) ) is now available.
On March 18, 2026, Azitra Inc. entered into a private placement securities purchase agreement with institutional and insider investors to sell Series A convertible preferred stock and accompanying Series B and C warrants. The PIPE financing, which closed on March 20, 2026, delivers initial gross proceeds of about $10.5 million and could reach roughly $31.4 million if all warrants are exercised for cash.
Each $1,000 share of Series A preferred is paired with long-dated warrants and is designed to automatically convert into common stock once shareholders approve an increase in authorized shares and related issuances. The structure, including strict beneficial ownership limits and potential pre-funded warrants, is intended to manage dilution and concentration while giving investors substantial upside exposure.
Azitra plans to use the proceeds, alongside existing cash, to fund research and development, general corporate purposes, and working capital, with a particular emphasis on launching new protein and peptide programs for cosmetic and cosmeceutical markets. Management highlighted that the financing will help harness the company’s microbial genetic engineering platform to produce high-value filaggrin-based ingredients, potentially accelerating time to commercialization and positioning Azitra to tap into the growing biotech cosmetic ingredients market, estimated at $2.3 billion in 2024.
The most recent analyst rating on (AZTR) stock is a Hold with a $0.27 price target. To see the full list of analyst forecasts on Azitra Inc stock, see the AZTR Stock Forecast page.
Spark’s Take on AZTR Stock
According to Spark, TipRanks’ AI Analyst, AZTR is a Neutral.
The score is driven primarily by weak financial performance (persistent losses, heavy cash burn, and an extreme 2025 deterioration), which elevates funding and continuity risk. Technicals add pressure given a clear downtrend and negative MACD, with oversold readings only offering limited offset. Valuation provides little support because the company is unprofitable and has no dividend yield.
To see Spark’s full report on AZTR stock, click here.
More about Azitra Inc
Azitra Inc. is a clinical-stage biopharmaceutical company focused on precision dermatology, developing engineered microbial therapies and protein technologies for serious skin conditions and cosmetic applications. Its lead programs, ATR-12 for Netherton syndrome and ATR-04 for EGFR inhibitor–associated rash, emerge from a proprietary platform that combines a 1,500-strain microbial library with AI-driven screening to generate therapeutic and cosmeceutical candidates.
The company is also advancing proprietary filaggrin protein and peptide technologies for the consumer and cosmeceutical markets, targeting skin barrier deficiencies linked to fine lines, wrinkles, dry sensitive skin, and eczema-like rashes. Azitra aims to leverage its microbial genetic engineering capabilities not only for prescription therapeutics but also to manufacture innovative proteins and peptides for the cosmetic and research markets, expanding its addressable opportunity beyond rare dermatologic diseases.
Average Trading Volume: 11,883,591
Technical Sentiment Signal: Sell
Current Market Cap: $4.58M
For a thorough assessment of AZTR stock, go to TipRanks’ Stock Analysis page.